Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
CD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despite these recent advances, the success of CD3 bsAbs in solid cancer has been hampered by hurdles like...
Saved in:
Main Authors: | Katy Lloyd, Jim Middelburg, Vitalijs Ovcinnikovs, Nora Pencheva, Kristel Kemper, Thorbald van Hall |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1548446/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01) -
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01) -
Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01) -
Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01) -
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)